TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Evotec AG ( (EVO) ) has issued an announcement.
On December 8, 2025, Evotec SE announced the completion of its sale of the Just – Evotec Biologics Toulouse site to Sandoz AG, effective December 5, 2025. The transaction, valued at over $650 million, includes cash payments, technology license fees, and potential royalties on biosimilars. This move aligns with Evotec’s strategy to focus on its core strengths and transition to a scalable technology provider, enhancing its revenue mix and profit margins. The sale is expected to improve Evotec’s operational efficiency and support its growth in biologics manufacturing.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
Evotec AG’s overall stock score is primarily impacted by its weak financial performance and concerning valuation metrics. The company is struggling with profitability and cash flow issues, reflected in a negative P/E ratio and lack of dividend yield. Technical analysis shows a bearish trend, further weighing on the score. Despite some positive developments from the earnings call, such as growth in the Biologics segment and strategic partnerships, these are not enough to offset the significant financial challenges.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a life science company that specializes in drug discovery and development, integrating breakthrough science with AI-driven innovation and advanced technologies. The company offers expertise in small molecules, biologics, cell therapies, and associated modalities, supported by proprietary platforms. Evotec collaborates with top pharmaceutical companies, biotechs, academic institutions, and healthcare stakeholders, focusing on therapeutic areas such as oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Average Trading Volume: 63,037
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.12B
For an in-depth examination of EVO stock, go to TipRanks’ Overview page.